Caribou Biosciences named finalist for 2026 Best Oncology R and D Advance for vispa-cel

Traders Union
All News
Business & Wealth
Companies
Caribou Biosciences finalist for award

Top Stories

Editors' Picks

Stocks

Crypto

Economics

Currencies

Commodities

Business & Wealth

Market Voices

Daria Chernytska

28.09.2026

Caribou Biosciences named finalist for 2026 Best Oncology R and D Advance for vispa-cel — Caribou Biosciences finalist for award

Caribou Biosciences has been selected as a finalist for Citeline's 2026 Best Oncology R and D Advance Award for its vispa-cel therapy. The recognition highlights vispa-cel, a pivotal-ready allogeneic CAR-T cell therapy aimed at expanding treatment access for cancer patients.

The award selection underscores Caribou Biosciences progress in developing innovative cancer therapies. The list of all finalists is available on Citeline's website.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

#Caribou

Editor's Picks for You

Tom Lee’s Ethereum bet: Why he expects another crypto boom

By Mikhail Vnuchkov
10 hours ago

Tom Lee’s Ethereum bet: Why he expects another crypto boom

Editors' Picks

How Paul McCartney became a billionaire and the role the stock market played

By Eugene Komchuk
14 hours ago

How Paul McCartney became a billionaire and the role the stock market played

Editors' Picks

Buterin’s new vision: Why Ethereum wants to become digital gold

By Olena Litvinenko
Yesterday

Buterin’s new vision: Why Ethereum wants to become digital gold

Editors' Picks

All Editors' Top Picks

Latest Caribou News

Caribou Biosciences abstracts chosen for three ASH26 presentations on novel cell therapies

By Mykhailo Ihnatenko
04.11.2026

Caribou Biosciences abstracts chosen for three ASH26 presentations on novel cell therapies

Companies

Capital shortage prompts Caribou Biosciences to halt allogeneic CAR-T therapy initiatives

By Yulia Slavina
06.10.2026

Capital shortage prompts Caribou Biosciences to halt allogeneic CAR-T therapy initiatives

Companies

Second quarter revenue and strategy update from Caribou Biosciences

By Anastasiia Chabaniuk
13.08.2026

Second quarter revenue and strategy update from Caribou Biosciences

Companies

All Caribou News

Mikhail Vnuchkov
10 hours ago

Tom Lee’s Ethereum bet: Why he expects another crypto boom

Eugene Komchuk
14 hours ago

How Paul McCartney became a billionaire and the role the stock market played

Olena Litvinenko
Yesterday

Buterin’s new vision: Why Ethereum wants to become digital gold

Anastasiia Chabaniuk
Yesterday

From affair to market crash: How the Nvidia scandal hit Bitcoin

Dmytro Kharkov
Yesterday

Shield AI’s Echodyne deal and the global counter-drone race

Mykhailo Ihnatenko
15 min ago

Nick Tomaino: Polymarket revenue and volume growth accelerating as U.S. app expands

Eugene Komchuk
32 min ago

Raoul Pal: After 2008, global debt levels led central banks to print money

Ksenia Gerey
36 min ago

Peter Brandt: Pullback in U.S. 30-year yield is finished, higher rates expected

Hanna Syniavska
38 min ago

Eric Lombardi: U.S. government spending rises with high taxes and dysfunctional systems

Alena Volkova
40 min ago

Rory Johnston: Major correction to reported U.S. crude, Cushing, gasoline, and distillate figures

Top News

Ivan Andriyenko
7 hours ago

U.S. core inflation beats forecasts for third consecutive month

U.S. core inflation beats forecasts for third consecutive month

Eugene Komchuk
8 hours ago

Public companies have sold $8 billion in Bitcoin so far in 2026

Public companies have sold $8 billion in Bitcoin so far in 2026

Andrey Mastykin
8 hours ago

Oil prices tumble as fears of Iran escalation fade

Oil prices tumble as fears of Iran escalation fade

Hanna Syniavska
10 hours ago

U.S. stock futures trade mixed ahead of crucial inflation report

U.S. stock futures trade mixed ahead of crucial inflation report

Igor Krasulya
11 hours ago

Fed Governor Waller warns inflation could justify 50-basis-point rate hike

Fed Governor Waller warns inflation could justify 50-basis-point rate hike

Top 5 companies for you

United States

Live News

Kyle Torpey
Now

Binance hackers launder stolen funds through Elon Musk-themed memecoins

Mykhailo Ihnatenko
Now

Intel stock forecast: Can CPI volatility derail the rebound toward 70?

Jose Antonio Gastelum
Now

Polymarket widens lead over Kalshi in political prediction markets

Anton Kharitonov
Now

EUR/USD holds above 1.1200 as traders await U.S. inflation data

Eugene Komchuk
Now

BitGo revenue halves amid crypto trading slowdown

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.